Τίτλος:
Attainment of Inactive Disease Following Discontinuation of Adalimumab Monotherapy in Patients with Enthesitis-Related Arthritis: A Real-Life, Dual-Center Experience
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
The optimum duration of treatment in patients with juvenile idiopathic arthritis (JIA), including enthesitis-related arthritis (ERA), is an area of pivotal concern for both parents and physicians. Novel medicines have managed to achieve remission of this otherwise debilitating condition1; however, issues regarding the duration and the best timing for termination of therapy endure.2 Enthesitis-related arthritis remains one of the most challenging JIA subtypes in terms of drug management and withdrawal. We report the results of a medical records review study aiming to describe the long-term outcome of children with a specific subcategory of ERA, solely treated with a tumor necrosis factor inhibitor (TNFi) (adalimumab [ADA]), in whom treatment was discontinued, following sustained clinical remission, and to identify potential relapse-associated risk factors. © 2022 Lippincott Williams and Wilkins. All rights reserved.
Συγγραφείς:
Papailiou, S.
Dasoula, F.
Tsolia, M.N.
Maritsi, D.N.
Περιοδικό:
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
Εκδότης:
Lippincott Williams and Wilkins
Λέξεις-κλειδιά:
adalimumab; antirheumatic agent, human; juvenile rheumatoid arthritis; treatment outcome, Adalimumab; Antirheumatic Agents; Arthritis, Juvenile; Humans; Treatment Outcome
DOI:
10.1097/RHU.0000000000001762
